Moreover, shRNA-mediated inhibition of NKX2-1 expression is reported to enhance the metastatic potential of KRASG12D/TP53Null-driven lung cancer cells (Winslow et al., 2011). This evidence concerns the gene NKX2-1 and lung carcinoma.